UNITY Biotechnology, Inc. is a cutting-edge biotechnology company based in South San Francisco, CA, dedicated to developing therapeutics that target age-related diseases. Their innovative approach focuses on selectively eliminating or modulating senescent cells, which may restore aging or damaged tissues to a healthier state. With a particular emphasis on vision loss and cognitive decline, UNITY aims to treat these diseases while reducing healthcare costs and alleviating the burden on individuals, families, and communities.
At the forefront of their research is UBX1325, the first senolytic approach designed to target senescent cells in the diseased vasculature of the eye, specifically for diabetic macular edema (DME). By providing a viable alternative to current treatment modalities, UNITY Biotechnology aims to revolutionize ophthalmology and transform the lives of individuals suffering from DME, the leading cause of blindness in adults with diabetes.
Generated from the website